Results Highlights

Highlights: FY2017 Results (As of May 9, 2018)

  • Net sales:
    • Solid overall sales performance across all businesses
    • Positive impact from the consolidation of CSP* in composites
      * Continental Structural Plastics Holdings Corporation: Became a consolidated subsidiary in January 2017
  • Operating income: 
    • Strong sales of aramid fibers, plastics and pharmaceuticals
    • The upfront payment from Merck* in FY17
      * The impact of licensing out of an investigational antibody candidate targeting tau for a possible new treatment of Alzheimer’s disease
    • Withdrawal from the unprofitable U.S. home healthcare business contributed to earnings growth
  • Profit attributable to owners of parent: 
    • Operating income increased
    • FY17: Recorded gain on sales of noncurrent assets
    • FY16: Includes special factors of approx. ¥11.0 billion (gain) associated with the withdrawal from the U.S. home healthcare business

In the fiscal year 2017, ending March 31, 2018, consolidated net sales for amounted to 835.0 billion yen, increased +93.7 billion yen compared with 741.3 billion yen for the fiscal 2016. Operating income for the fiscal 2017 were 69.8 billion yen, increased +13.3 billion yen compared with 56.5 billion yen for the fiscal 2016. Ordinary income for the fiscal 2017 amounted to 67.8 billion yen, increased +11.9billion yen compared with 55.9 billion yen for the fiscal 2016. Profit attributable to owners of parent of 45.6 billion yen for the fiscal 2017, down -4.6 billion yen compared with 50.1 billion yen in the fiscal 2016.

otal assets as of March 31, 2018, amounted to 986.2 billion yen, increase of +22.1 billion yen from the end of fiscal 2016 (964.1 billion yen). Shareholders´ equity was 392.9 billion yen, increase of +54.5 billion yen compared with 338.4 billion yen. Interest-bearing debt was down -32.0 billion yen, from 376.2 billion yen at the end of fiscal 2016 to 344.2 billion yen.

* Profit attributable to owners of parent